30.04.2009, 16:46 Uhr, Gesundheit & Medizin Cystic fibrosis ­ Orphan drug designation for innovative treatment against lung infections by Axentis Pharma AG Zurich, 30 April 2009. An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received orphan drug designation in the US. Axentis Pharma of Zurich, Switzerland announced today that this sought-after designation has been granted to …